Post-Market Study of Low-flow ECCO2R Using PrismaLung+ : A Post-Market Study of Performance and Safety of Low-flow Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Patients With Mild to Moderate Acute Respiratory Distress Syndrome
PrismaLung+ is indicated to provide extracorporeal carbon dioxide removal (ECCO2R) as a stand-alone therapy or in combination with continuous renal replacement therapy (CRRT). This study is intended for patients with increased levels of Carbon Dioxide (CO2) in their blood and ≥ 18 years old, and will treat patients with mild or moderate acute respiratory distress syndrome (ARDS) using PrismaLung+. The study will assess tidal volume reduction and confirm the safety of PrismaLung+..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 02. Aug. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: November 5, 2020, Last downloaded: ClinicalTrials.gov processed this data on August 09, 2023, Last updated: August 09, 2023 |
---|
Study ID: |
NCT04617093 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003567508 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003567508 | ||
003 | DE-627 | ||
005 | 20230809010758.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003567508 | ||
035 | |a (UBBS_Klinische_Studien)NCT04617093 | ||
035 | |a (UBBS_Klinische_Studien)BXU542357 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Post-Market Study of Low-flow ECCO2R Using PrismaLung+ |b A Post-Market Study of Performance and Safety of Low-flow Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Patients With Mild to Moderate Acute Respiratory Distress Syndrome |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: November 5, 2020, Last downloaded: ClinicalTrials.gov processed this data on August 09, 2023, Last updated: August 09, 2023 | ||
520 | |a PrismaLung+ is indicated to provide extracorporeal carbon dioxide removal (ECCO2R) as a stand-alone therapy or in combination with continuous renal replacement therapy (CRRT). This study is intended for patients with increased levels of Carbon Dioxide (CO2) in their blood and ≥ 18 years old, and will treat patients with mild or moderate acute respiratory distress syndrome (ARDS) using PrismaLung+. The study will assess tidal volume reduction and confirm the safety of PrismaLung+. | ||
650 | 2 | |a Respiratory Distress Syndrome | |
650 | 2 | |a Respiratory Distress Syndrome, Newborn | |
650 | 2 | |a Acute Lung Injury | |
650 | 2 | |a Syndrome | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 02. Aug. |
773 | 1 | 8 | |g year:2023 |g day:02 |g month:08 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04617093 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 02 |c 08 |